Morgan Stanley Downgrades ResMed to Equal-Weight, Lowers Price Target to $230

Benzinga Newsdesk www.benzinga.com Negative 89.2%

Neg 89.2% Neu 0% Pos 0%

Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight and lowers the price target from $286 to $230.